Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
59
BOUT Quote, Financials, Valuation and Earnings
Last price:
$36.98
Seasonality move
:
3.98%
Day range:
$36.60 - $37.02
52-week range:
$31.08 - $42.41
Dividend yield:
0.63%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.4K
Avg. volume:
2.6K
1-year change:
-12.8%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | -- | -- | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | -- | -- | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | -- | -- | -- | -- |
|
MID
American Century Mid Cap Growth Impact ETF
|
-- | -- | -- | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
$36.91 | -- | -- | -- | $0.23 | 0.63% | -- |
|
FFTY
Innovator IBD 50 ETF
|
$35.39 | -- | -- | -- | $0.26 | 0.73% | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
$167.27 | -- | -- | -- | $0.53 | 0.44% | -- |
|
IPO
Renaissance IPO ETF
|
$46.70 | -- | -- | -- | $0.18 | 0.72% | -- |
|
MID
American Century Mid Cap Growth Impact ETF
|
$67.25 | -- | -- | -- | $0.03 | 0.17% | -- |
|
TMFX
Motley Fool Next Index ETF
|
$21.59 | -- | -- | -- | $0.01 | 0.06% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | 1.050 | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | 1.833 | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | 1.967 | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | 1.770 | -- | -- |
|
MID
American Century Mid Cap Growth Impact ETF
|
-- | 1.206 | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | 1.329 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- | -- |
|
FPX
First Trust US Equity Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
IPO
Renaissance IPO ETF
|
-- | -- | -- | -- | -- | -- |
|
MID
American Century Mid Cap Growth Impact ETF
|
-- | -- | -- | -- | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | -- | -- | -- | -- | -- |
Innovator IBD Breakout Opportunities ETF vs. Competitors
-
Which has Higher Returns BOUT or FFTY?
Innovator IBD 50 ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat Innovator IBD 50 ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- FFTYInnovator IBD 50 ETF-- -- -- -
What do Analysts Say About BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Innovator IBD 50 ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than Innovator IBD 50 ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than Innovator IBD 50 ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 FFTYInnovator IBD 50 ETF0 0 0 -
Is BOUT or FFTY More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 1.020, which suggesting that the stock is 2.017% more volatile than S&P 500. In comparison Innovator IBD 50 ETF has a beta of 1.405, suggesting its more volatile than the S&P 500 by 40.503%.
-
Which is a Better Dividend Stock BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.63%. Innovator IBD 50 ETF offers a yield of 0.73% to investors and pays a quarterly dividend of $0.26 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. Innovator IBD 50 ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than Innovator IBD 50 ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than Innovator IBD 50 ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while Innovator IBD 50 ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for Innovator IBD 50 ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- FFTYInnovator IBD 50 ETF-- -- -- --
-
Which has Higher Returns BOUT or FPX?
First Trust US Equity Opportunities ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat First Trust US Equity Opportunities ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- FPXFirst Trust US Equity Opportunities ETF-- -- -- -
What do Analysts Say About BOUT or FPX?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust US Equity Opportunities ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than First Trust US Equity Opportunities ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than First Trust US Equity Opportunities ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 FPXFirst Trust US Equity Opportunities ETF0 0 0 -
Is BOUT or FPX More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 1.020, which suggesting that the stock is 2.017% more volatile than S&P 500. In comparison First Trust US Equity Opportunities ETF has a beta of 1.235, suggesting its more volatile than the S&P 500 by 23.497%.
-
Which is a Better Dividend Stock BOUT or FPX?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.63%. First Trust US Equity Opportunities ETF offers a yield of 0.44% to investors and pays a quarterly dividend of $0.53 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. First Trust US Equity Opportunities ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or FPX?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than First Trust US Equity Opportunities ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than First Trust US Equity Opportunities ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while First Trust US Equity Opportunities ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for First Trust US Equity Opportunities ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- FPXFirst Trust US Equity Opportunities ETF-- -- -- --
-
Which has Higher Returns BOUT or IPO?
Renaissance IPO ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat Renaissance IPO ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- IPORenaissance IPO ETF-- -- -- -
What do Analysts Say About BOUT or IPO?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Renaissance IPO ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than Renaissance IPO ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than Renaissance IPO ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 IPORenaissance IPO ETF0 0 0 -
Is BOUT or IPO More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 1.020, which suggesting that the stock is 2.017% more volatile than S&P 500. In comparison Renaissance IPO ETF has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.379%.
-
Which is a Better Dividend Stock BOUT or IPO?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.63%. Renaissance IPO ETF offers a yield of 0.72% to investors and pays a quarterly dividend of $0.18 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. Renaissance IPO ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or IPO?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than Renaissance IPO ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than Renaissance IPO ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while Renaissance IPO ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for Renaissance IPO ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- IPORenaissance IPO ETF-- -- -- --
-
Which has Higher Returns BOUT or MID?
American Century Mid Cap Growth Impact ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat American Century Mid Cap Growth Impact ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- MIDAmerican Century Mid Cap Growth Impact ETF-- -- -- -
What do Analysts Say About BOUT or MID?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand American Century Mid Cap Growth Impact ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than American Century Mid Cap Growth Impact ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than American Century Mid Cap Growth Impact ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 MIDAmerican Century Mid Cap Growth Impact ETF0 0 0 -
Is BOUT or MID More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 1.020, which suggesting that the stock is 2.017% more volatile than S&P 500. In comparison American Century Mid Cap Growth Impact ETF has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.254%.
-
Which is a Better Dividend Stock BOUT or MID?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.63%. American Century Mid Cap Growth Impact ETF offers a yield of 0.17% to investors and pays a quarterly dividend of $0.03 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. American Century Mid Cap Growth Impact ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or MID?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than American Century Mid Cap Growth Impact ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than American Century Mid Cap Growth Impact ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while American Century Mid Cap Growth Impact ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for American Century Mid Cap Growth Impact ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- MIDAmerican Century Mid Cap Growth Impact ETF-- -- -- --
-
Which has Higher Returns BOUT or TMFX?
Motley Fool Next Index ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat Motley Fool Next Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- TMFXMotley Fool Next Index ETF-- -- -- -
What do Analysts Say About BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Motley Fool Next Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than Motley Fool Next Index ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than Motley Fool Next Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 TMFXMotley Fool Next Index ETF0 0 0 -
Is BOUT or TMFX More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 1.020, which suggesting that the stock is 2.017% more volatile than S&P 500. In comparison Motley Fool Next Index ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.23 per share corresponding to a yield of 0.63%. Motley Fool Next Index ETF offers a yield of 0.06% to investors and pays a quarterly dividend of $0.01 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. Motley Fool Next Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than Motley Fool Next Index ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than Motley Fool Next Index ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while Motley Fool Next Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for Motley Fool Next Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- TMFXMotley Fool Next Index ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 105.84% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 1.85% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.66% over the past day.
